This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

2013 China Human Immunoglobulin (pH4) For Intravenous Injection Industry Research Report

DUBLIN, November 12, 2013 /PRNewswire/ --

Research and Markets ( http://www.researchandmarkets.com/research/3szzdk/2013_china_human) has announced the addition of the "2013 China Human Immunoglobulin (pH4) for Intravenous Injection Industry Research Report" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

This 2013 research report is a professional and in-depth research report on the Chinese Human Immunoglobulin (pH4) for Intravenous Injection industry. This report firstly discusses the definition, classification, industry chain and other related information of this industry.

It then reviews manufacturing technology, product specifications and summary statistics of 25 major Chinese manufacturers 2010-2016 giving details on capacity, production, supply, demand, shortage, selling price, cost, gross margin, production value and market share.

In the end, this report discusses the 200K Bottles/year project feasibility analysis and investment return analysis, and gives related research conclusions and development trend analysis of the Chinese Human Immunoglobulin (pH4) for Intravenous Injection industry.

Key Topics Covered: Chapter One Human Immunoglobulin (pH4) for Intravenous Injection Industry Overview

Chapter Two Human Immunoglobulin (pH4) for Intravenous Injection Manufacturing Process and Cost Analysis

Chapter Three Human Immunoglobulin (pH4) for Intravenous Injection Production Supply Sales Demand Market Status and Forecast

Chapter Four Human Immunoglobulin (pH4) for Intravenous Injection Key Manufacturers Analysis

Chapter Five Human Immunoglobulin (pH4) for Intravenous Injection Project Investment Feasibility Analysis

Chapter Six Human Immunoglobulin (pH4) for Intravenous Injection Industry Research Conclusions

Companies Mentioned - Banghe Pharmaceutical Co.,Ltd. - Boya Biological (300294) - CTBB - Greencross( China) - Guangdong Shuanglin Bio-pharmacy Co.,Ltd. - Guangdong Weilun Biological Pharmaceutical Co.,Ltd. - Guizhou Taibang Biological Products Co.,Ltd. - Guizhou Zhongtai Biological S&T Co.,Ltd. - Haikang Biological Products Co.,Ltd. - Hualan Bio (002007) - Hunan Unisplendour Guhan Nanyue-pharmaceutical Co.,Ltd. (000590) - Lanzhou Institute of Biological Products Co.,Ltd. - PAFC - Ronsen Pharmaceutical - Shanghai Institute of Biological Products Co.,Ltd. - Shanghai RAAS (002252) - Shanghai Xinxing Medicine Co.,Ltd. - Shanxi Kangbao Biological Product Co.,Ltd. - Shenzhen Weiwuguangming Biological Products Co.,Ltd. - Sichuan Yuanda Shuyang Pharmaceutical Co.,Ltd. - Tonrol Pharmaceutical - Walvax Biotechnology Co.,Ltd. (300142) (Hebei Daan) - Wuhan Institute of Biological Products Co.,Ltd. - Wuhan Zhongyuan Ruide Biological Products Co.,Ltd. - Xi'an Huitian Blood Products Co.,Ltd. For more information visit http://www.researchandmarkets.com/research/3szzdk/2013_china_human.

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com U.S. Fax: +1-646-607-1907 Fax (outside U.S.): +353-1-481-1716 Sector: Pharmaceuticals

SOURCE Research and Markets

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs